文献速递免疫规划传染病防控与疫情报告

巴西3-4岁儿童接种BNT162b2与CoronaVac疫苗降低COVID-19严重结局的效果

Effectiveness of BNT162B2 and CoronaVac vaccines in reducing COVID-19 severity among children aged 3-4 years in Brazil.
PubMed 文献 · Vaccine · 2026-07-29

该研究基于巴西全国人群队列,评估3-4岁儿童接种BNT162b2和CoronaVac对COVID-19相关严重结局的效果。结果显示,部分接种对住院的保护效果为79.0%(95%CI 69.9%-85.4%),完成基础免疫为49.2%(95%CI 32.5%-61.9%);完成基础免疫的儿童中无死亡发生。

要点

  • 部分接种对COVID-19相关住院的保护效果为79.0%,完成基础免疫为49.2%。
  • 对侵袭性机械通气的保护效果分别为77.6%和79.1%。
  • 完成基础免疫的儿童中未发生死亡。

核心结论

  • 以CoronaVac为主的COVID-19疫苗接种与3-4岁儿童严重结局显著减少相关,支持儿科免疫策略和公共卫生工作。

研究设计与样本

  • 全国性人群队列研究,评估2022年第31-52周和2023年第1-13周期间3-4岁儿童按疫苗接种状态(未接种、1剂、2剂)的COVID-19相关严重急性呼吸综合征住院、侵袭性通气支持和死亡的发病率比。
  • 数据来自OpenDATASUS的实验室确诊COVID-19相关住院、临床结局和疫苗接种状态,疫苗接种覆盖率来自巴西卫生部COVID-19疫苗接种仪表板。

主要发现

  • 研究期间CoronaVac基础免疫完成率增至15%,BNT162b2增至2%,分别对应797,956人和79,650人接种第二剂。
  • 共963名儿童因COVID-19相关严重急性呼吸综合征住院。
  • 部分接种对住院的疫苗有效性为79.0%(95%CI 69.9%-85.4%),完成基础免疫为49.2%(95%CI 32.5%-61.9%)(p < 0.01)。
  • 对侵袭性机械通气的有效性分别为77.6%和79.1%;完成基础免疫的儿童中无死亡发生。
  • 因BNT162b2接种者比例较低,无法进行疫苗间直接比较。

临床怎么用

  • 在3-4岁儿童中推进COVID-19疫苗接种,尤其是以CoronaVac为主的基础免疫,可降低COVID-19相关住院和侵袭性通气支持风险。

局限性

  • 因BNT162b2接种者比例较低,无法直接比较两种疫苗的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: National population-based databases from large countries can provide real-world estimates of COVID-19 vaccine effectiveness. This analysis examined the effectiveness of BNT162b2 and CoronaVac against severe COVID-19-related outcomes in children aged 3 to 4 years during the Omicron phase of the pandemic in Brazil. METHODS: This nationwide population-based cohort study assessed incidence rate ratios for hospitalization due to COVID-19-associated severe acute respiratory syndrome, invasive ventilatory support, and death among children aged 3 to 4 years, according to vaccination status (unvaccinated, 1 dose, or 2 doses), during 2022-2023. The study period spanned epidemiological weeks 31-52 of 2022 and weeks 1-13 of 2023. Data on laboratory-confirmed COVID-19-related hospitalizations, clinical outcomes, and vaccination status were obtained from OpenDATASUS, and vaccination coverage was estimated using data from the Brazilian Ministry of Health COVID-19 vaccination dashboard. RESULTS: Among children aged 3 to 4 years completion of the primary series increased to 15% for CoronaVac and 2% for BNT162b2 during the study period, corresponding to 797,956 and 79,650 individuals receiving the second dose, respectively. A total of 963 children were hospitalized with COVID-19-associated severe acute respiratory syndrome. Vaccine effectiveness against hospitalization was 79.0% (95% CI, 69.9%-85.4%) after partial vaccination and 49.2% (95% CI, 32.5%-61.9%) after completion of the primary series (p < 0.01). Effectiveness against invasive mechanical ventilation was 77.6% and 79.1%, respectively; no deaths occurred among fully vaccinated children. Direct comparisons between vaccines were not feasible because of the lower proportion of BNT162b2 recipients. CONCLUSIONS: COVID-19 vaccination, predominantly based on the CoronaVac vaccine, was associated with a significant reduction in severe outcomes among children aged 3-4 years, providing robust evidence to support pediatric immunization strategies and public health efforts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. de Padua MC, Antunes MOB, Stein RT, et al. Effectiveness of BNT162B2 and CoronaVac vaccines in reducing COVID-19 severity among children aged 3-4 years in Brazil. Vaccine. 2026. PMID: 42526176. doi:10.1016/j.vaccine.2026.128974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。